ArticleExperimental and therapeutic medicine2025
Value of hs-cTnT, sST2, and Lp-PLA2 in the classification of acute coronary syndrome.
Article in Experimental and therapeutic medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to assess the value of high-sensitivity cardiac troponin T (hs-cTnT), soluble suppression of tumorigenicity 2 protein (sST2) and lipoprotein-associated phospholipase A2 (Lp-PLA2) in the classification of acute coronary syndrome (ACS). A total of 236 patients diagnosed with ACS were enrolled in this retrospective study and were further divided into the non-ST-segment-elevation (NSTE)-ACS group (n=183) and ST-segment elevation myocardial infarction (STEMI) group (n=53). The three biomarkers (hs-cTnT, sST2 and Lp-PLA2) were measured by electrochemiluminescence. The diagnostic performance of each biomarker in differentiating ACS subtypes was evaluated through receiver operating characteristic curve analysis. The DeLong test was applied to compare the discriminatory abilities of the different markers. The binary logistic regression model was employed to analyze the factors influencing ACS classification. The levels of hs-cTnT and sST2 in males were significantly higher in the STEMI group than in the NSTE-ACS group (P<0.05). hs-cTnT [odds ratio (OR)=1.010, 95% CI: 1.007-1.014] and sST2 (OR=1.022, 95% CI: 1.011-1.033) were identified as good predictors for distinguishing STEMI from NSTE-ACS, whereas Lp-PLA2 (P=0.470) was not a suitable biomarker to discriminate between the two types of ACS. Additionally, the diagnostic efficacy of hs-cTnT [area under curve (AUC=0.861)] and the combination of hs-cTnT and sST2 (AUC=0.863) was higher than that of sST2 alone (AUC=0.833, P<0.05). In conclusion, these findings illustrated that hs-cTnT and sST2 are promising biomarkers to classify patients with ACS. Compared with sST2 alone, hs-cTnT and its combined detection demonstrate superior diagnostic efficiency in identifying ACS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.